Results 91 to 100 of about 11,492 (188)
AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes
Clinical &Experimental Allergy, EarlyView.ABSTRACT The AllergoOncology field brings together the study of allergic and cancer immune responses, having evolved from early epidemiological studies that reported inverse associations between allergies, IgE and cancer risk. Insights from studying allergic inflammation are revealing previously unappreciated immune mechanisms that confer protective ...
Jakub Zydron +13 more
wiley +1 more source
Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis
Allergy & Rhinology, 2017 Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed.
Mark R. Peterson D.O. +1 more
doaj +1 more source
Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]
, 2018 According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca +6 more
core +2 more sources
How to evaluate a patient's response to anti-IgE
European Respiratory Review, 2007 Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled ...
S. T. Holgate
doaj
Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
Case Reports in Dermatology, 2012 Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising ...
Ilya Ivyanskiy +2 more
doaj +1 more source
Estudio de utilización de omalizumab y mepolizumab en asma refractaria grave [PDF]
, 2018 Introducción. En los últimos años, se han comercializado diferentes fármacos biológicos dirigidos a dianas específicas del asma, como el omalizumab y mepolizumab.
López Cárdenas, Mª Teresa
core
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma
, 2019 Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean +6 more
core +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche +7 more
wiley +1 more source
ERJ Open Research, 2019 Background Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness.
Katia M.C. Verhamme +4 more
doaj +1 more source
Wells syndrome: clinical findings and management in a large cohort of 48 patients
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and Objectives: Wells syndrome (WS) is a rare inflammatory skin disorder typically characterized by erythematous, edematous, and pruritic plaques. Despite its distinct histopathological features, WS remains an underdiagnosed disease due to its variable clinical presentations and overlap with other dermatological conditions.
Marco Adriano Chessa +8 more
wiley +1 more source